State Street SPDR S&P Biotech ETF

XBI

시가총액 US$95.4억

Shares of AbbVie, Eli Lilly and Gilead Sciences are trading at or near record highs.

Healthcare stocks have finally stepped back into the spotlight. After spending much of the past several years in the shadow of technology and AI, the sector has quietly emerged as one of the year's more compelling comeback stories.

Biotechnology stocks are showing signs of a renewed recovery, supported by a pickup in pharmaceutical mergers and acquisitions and investor interest in drug development pipelines. Key Takeaways: Big pharma acquisitions are hitting record highs to combat impending patent cliffs.

Pharmaceutical Research and ​Manufacturers of ‌America, the pharmaceutical ​industry lobbying ​group, sued the ⁠Trump ​administration on Wednesday, ​court records show.

Salveen Richter, Goldman Sachs lead U.S. biotech analyst, joins 'Closing Bell Overtime' to talk biotech innovations in China.

The Fidelity MSCI Health Care Index ETF offers a significantly lower expense ratio and a more diversified portfolio than the State Street SPDR S&P Biotech ETF. The State Street SPDR S&P Biotech ETF experienced a much deeper maximum drawdown over the last five years but outperformed on a 1-year total return basis.

The State Street SPDR S&P Biotech ETF and State Street SPDR S&P Pharmaceuticals ETF carry identical 0.35% expense ratios. The State Street SPDR S&P Pharmaceuticals ETF has historically exhibited significantly lower price volatility and a smaller maximum drawdown than its biotech counterpart.

Making its debut on 01/31/2006, smart beta exchange traded fund State Street SPDR S&P Biotech ETF (XBI) provides investors broad exposure to the Health Care ETFs category of the market.

The State Street SPDR S&P Biotech ETF has likely peaked after a 60% rally over the past year. Key tailwinds—practice-changing drug approvals, pharma M&A, and lower rates—have faded as the rate cycle has reversed. Equity supply in biotech is at cycle peak levels, signaling potential headwinds for further upside.

VHT offers significantly lower ownership costs, with a 0.09% expense ratio compared to XBI's 0.35%. XBI provides targeted focus on biotechnology, while VHT offers exposure to the entire healthcare sector.